Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes

Bibliographic Details
Main Authors: Jean Galtier, Camille Alric, Emilie Bérard, Thibaut Leguay, Suzanne Tavitian, Audrey Bidet, Eric Delabesse, Jean Baptiste Rieu, Jean-Philippe Vial, François Vergez, Nicolas Lechevalier, Isabelle Luquet, Emilie Klein, Anne-Charlotte de Grande, Audrey Sarry, Arnaud Pigneux, Christian Récher, Sarah Bertoli, Pierre-Yves Dumas
Format: Article
Language:English
Published: Nature Publishing Group 2021-11-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00551-y

Internet

https://doi.org/10.1038/s41408-021-00551-y

Similar Items